You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Related products

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-Cytokeratin 5 antibody [EP1601Y] (ab52635)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-Cytokeratin 5 antibody [EP1601Y]
See all Cytokeratin 5 products (13) ...

Description

Rabbit monoclonal [EP1601Y] to Cytokeratin 5

Specificity

Mouse reactivity is based on IHC ( positive tissues: liver,lung,brain,skin). However, WB was negative for Mouse brain, heart, kidney and spleen.

Tested applications

IHC-Fr, ICC/IF, IHC-P, WB, IHC-Pmore details

Cross reactivity

Reacts with

Mouse, Human

Does not react with

Rat

Immunogen

Synthetic peptide (Human)

Positive control

A431 cells. Human transitional urinary bladder carcinoma.

General notes

Produced under U.S. Patent No. 5,675,063.

Properties

Form

Liquid

Storage instructions

Store at -20°C. Stable for 12 months at -20°C

Storage buffer

Preservative: 0.01% Sodium Azide
Constituents: 40% Glycerol, 0.05% BSA, 0.15M Sodium chloride, 50mM Tris glycine, pH 7.4

Purity

Tissue culture supernatant

Clonality

Monoclonal

Clone number

EP1601Y

Isotype

IgG

  • Western blot - Cytokeratin 5 antibody [EP1601Y] (ab52635)Western blot - Cytokeratin 5 antibody [EP1601Y] (ab52635) image (enlarge)

  • Immunohistochemistry (Paraffin-embedded sections) - Cytokeratin 5 antibody [EP1601Y] (ab52635)Immunohistochemistry (Paraffin-embedded sections) - Cytokeratin 5 antibody [EP1601Y] (ab52635) image (enlarge)

  • Immunocytochemistry/ Immunofluorescence - Cytokeratin 5 antibody [EP1601Y] (ab52635)Immunocytochemistry/ Immunofluorescence - Cytokeratin 5 antibody [EP1601Y] (ab52635) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab52635 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application notes

Is unsuitable for or Flow Cyt.

Target

Involvement in disease

Defects in KRT5 are a cause of epidermolysis bullosa simplex Dowling-Meara type (DM-EBS) [MIM:131760]. DM-EBS is a severe form of intraepidermal epidermolysis bullosa characterized by generalized herpetiform blistering, milia formation, dystrophic nails, and mucous membrane involvement.
Defects in KRT5 are the cause of epidermolysis bullosa simplex with migratory circinate erythema (EBSMCE) [MIM:609352]. EBSMCE is a form of intraepidermal epidermolysis bullosa characterized by unusual migratory circinate erythema. Skin lesions appear from birth primarily on the hands, feet, and legs but spare nails, ocular epithelia and mucosae. Lesions heal with brown pigmentation but no scarring. Electron microscopy findings are distinct from those seen in the DM-EBS, with no evidence of tonofilament clumping.
Defects in KRT5 are a cause of epidermolysis bullosa simplex Weber-Cockayne type (WC-EBS) [MIM:131800]. WC-EBS is a form of intraepidermal epidermolysis bullosa characterized by blistering limited to palmar and plantar areas of the skin.
Defects in KRT5 are a cause of epidermolysis bullosa simplex Koebner type (K-EBS) [MIM:131900]. K-EBS is a form of intraepidermal epidermolysis bullosa characterized by generalized skin blistering. The phenotype is not fundamentally distinct from the Dowling-Meara type, althought it is less severe.
Defects in KRT5 are the cause of epidermolysis bullosa simplex with mottled pigmentation (MP-EBS) [MIM:131960]. MP-EBS is a form of intraepidermal epidermolysis bullosa characterized by blistering at acral sites and 'mottled' pigmentation of the trunk and proximal extremities with hyper- and hypopigmentation macules.
Defects in KRT5 are the cause of Dowling-Degos disease (DDD) [MIM:179850]; also known as Dowling-Degos-Kitamura disease or reticulate acropigmentation of Kitamura. DDD is an autosomal dominant genodermatosis. Affected individuals develop a postpubertal reticulate hyperpigmentation that is progressive and disfiguring, and small hyperkeratotic dark brown papules that affect mainly the flexures and great skin folds. Patients usually show no abnormalities of the hair or nails.

Sequence similarities

Belongs to the intermediate filament family.

Target information above from: UniProt accessionP13647 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • type II cytoskeletal 5 antibody
  • 58 kDa cytokeratin antibody
  • CK-5 antibody
  • CK5 antibody
  • Cytokeratin-5 antibody
  • Cytokeratin5 antibody
  • DDD antibody
  • EBS2 antibody
  • K2C5_HUMAN antibody
  • K5 antibody
  • Keratin 5 antibody
  • Keratin antibody
  • Keratin-5 antibody
  • Keratin5 antibody
  • KRT 5 antibody
  • Krt5 antibody
  • Type-II keratin Kb5 antibody
see all

Anti-Cytokeratin 5 antibody [EP1601Y] images:

  Western blot - Cytokeratin 5 antibody [EP1601Y] (ab52635)

Western blot - Cytokeratin 5 antibody [EP1601Y] (ab52635)

Anti-Cytokeratin 5 antibody [EP1601Y] (ab52635) at 1/10000 dilution + A431 cell lysate at 10 µg

Secondary
Goat anti-rabbit HRP at 1/2000 dilution

Predicted band size : 62 kDa
Observed band size : 62 kDa

  Immunohistochemistry (Paraffin-embedded sections) - Cytokeratin 5 antibody [EP1601Y] (ab52635)

Immunohistochemistry (Paraffin-embedded sections) - Cytokeratin 5 antibody [EP1601Y] (ab52635)

Human transitional urinary bladder carcinoma stained with ab52635 at 1/100 - 1/250 dilution.

  Immunocytochemistry/ Immunofluorescence - Cytokeratin 5 antibody [EP1601Y] (ab52635)

Immunocytochemistry/ Immunofluorescence - Cytokeratin 5 antibody [EP1601Y] (ab52635)

A431 cells stained with ab52635 at 1/100 - 1/250

References for Anti-Cytokeratin 5 antibody [EP1601Y] (ab52635)

This product has been referenced in:

  • Tokar EJet al. Arsenic-specific stem cell selection during malignant transformation. J Natl Cancer Inst 102:638-49 (2010). ICC/IF; Human.Read more (PubMed: 20339138) »
  • Sun Yet al. Aberrant cytokeratin expression during arsenic-induced acquired malignant phenotype in human HaCaT keratinocytes consistent with epidermal carcinogenesis. Toxicology 262:162-70 (2009).Read more (PubMed: 19524636) »

See all 2 publications for this product

Publishing research using ab52635? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"